Cross Cancer Institute ( Site 0110)

Edmonton, Alberta T6G 1Z2

0 studies enrolling now · 1 studies all time

What they study most

Prostatic Neoplasms

Studies at this site

• Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010) — Completed